According to the Import Substitution Program
Issues of pharmaceutical support and pharmaceutical safety are at the focus of the CIS leaders. The matter was discussed during visit of the Russian President Vladimir Putin and President of Kazakhstan Nursultan Nazarbayev into the research center of the Russian biotechnological company BIOCAD.
This research center, established by BIOCAD for implementation of the proactive import substitution, this research center develops competences in the field of molecular biology, bioinformatics and genomics. The general director of BIOCAD Dmitry Morozov told his honored guests about the key directions of the center activities, told them about the key departments and laboratories developing breakthrough products for treatment of cancer.
The President of Kazakhstan Nursultan Nazarbayev is highly interested in the project. This year BIOCAD localized in Kazakhstan manufacture of rituximab – a high-tech drug based on monoclonal antibodies, intended for treatment of blood cancer, which has become possible thanks to cooperation with Karaganda pharmaceutical complex (Kazakhstan). The drug is approved in Kazakhstan ensuring effective and affordable alternative to a similar product which has been imported until recently.